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1. Introduction 
Traumatic brain injury has been major cause of mortality and morbidity worldwide, 
especially in children and young adults and it has been continuing a difficult problem in 
intensive care units. 
Brain trauma can be caused by a direct impact or by acceleration alone. In addition to the 
damage caused at the moment of injury, brain trauma causes secondary injury, a variety of 
events that take place in that minutes and/or days following the injury 
Secondary brain injury is attributable to a decrease in cerebral oxygen delivery as a result of 
hypertension, hypoxia, cerebral oedema, intracranial hypertension or abnormalities in 
cerebral blood flow. Although the severity of primary brain injury cannot be reduced, 
secondary brain injury can be minimised if appropriate therapies are implemented in time. 
The main aim in the traumatic brain injured patients must be to maintain a good result from 
primary injury caused by trauma and/or as a result of direct effect of trauma. 
The second aim must be to prevent secondary brain injury caused by as results of the 
complications. The basic principle in the care and treatment of traumatic brain injury is to 
describe and begin the treatment these complications that worsen the primary injury and 
lead to secondary brain injury. 
The main targets in these aims are: 
1. Maintain the cerebral energy metabolism by maintaining needed systemic support, 
2. Maintain cerebral perfusion pressure (CPP) in normal limits, 
3. Maintain ICP in normal limits as possible. 
The intensive care for traumatic brain injury should consist beside the control of ICP, 
respiratory system, central nervous system, and cirulatory system, it should also consist 
monitoring of metabolism especially glucose metabolism, temperature and electrolite 
balance in short intervals. With these invasive and noninvasive monitoring, all the 
precausions for the problems should be ready. 
www.intechopen.com
 
Emergency Medicine – An International Perspective 
 
2 
Beside heavy brain injury may result in a permanant neurologic sequale, it may also give a 
good results especially in young patients that aggresivelly lowered inreased ICP levels and 
optimized CPP and cerebral oxygenation by multidisiplinary approach with 
neurointensivist, neuroanesthesist and neurosurgeon. 
In this chapter we will discuss the intensive care management of severe TBI with emphasis 
on the specific measures directed for prevention and/or treatment of secondary brain injury 
2. Indication for admission to ICU 
The role of an intensive care unit is to maintain a patient’s normal physiological homeostasis 
while actively treating the underlying cause of any physiological derangement. Discussion will 
be targeted towards a number of areas; respiratory system, cardiovascular system, alimentary 
system, nasocomial infection and infection surveillance, anticoagulation, patient comfort. 
Indication for admission to ICU include 
 Impaired level of consciousness, 
 Impaired airway protection 
 Progressive respiratory impairment or the need for mechanical ventilation 
 Seizures 
 Clinical or computed tomographic (CT) evidence of raised ICP caused by a space 
occupying lesion , cerebral edema or haemorrhagic conversion of a cerebral infarct. 
 General medical complications (for example, hyper/hypotension, fluid and electrolyte 
disturbances, aspiration pneumonia,sepsis, cardiac arrhytmias, pulmonary embolism) 
 Monitoring (for example level of conciousness, respiratory function, ICP continuous 
electroencephalography(EEG) 
 Specific treatments(for example , neurosurgical intervention, intravenous or arterial 
trombolysis ) 
Mechanical ventilation 
Most patients admitted to neuro-intensive care require respiratory support because of 
hypoxaemia, ventilatory failure or due to treatment modalities requiring respiratory support. 
The support may range from oxygen therapy by face mask, through non-invasive 
techniques such as continuous positive airways pressure, to full ventilatory support with 
endotracheal intubation. 
Oxygen is usually given by face mask, although nasal prongs or cannulas may be well 
tolerated. 
If the patient remains hypoxaemic on high flow oxygen (15 l/min) continuous positive 
airways pressure (CPAP) may be used. The continuous positive airways pressure mask 
often becomes uncomfortable and gastric distension may occur. Patients must therefore be 
cooperative, able to protect their airway, and have the strength to breathe spontaneously 
and cough effectively. 
In patients with acute brain lesions at risk for cerebral ischemia, maintenance of adequate 
cerebral perfusion pressure (CPP), artificial ventilation for prevention of hypercapnia and deep 
sedation are all major determinants for actual strategies of a cerebroprotective therapy (1). 
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The patient who has an altered level of consciousness (GCS <8 ) and loss of gag/cough 
reflex often has deficits in a number of airway protection mechanisms or exhaustion need 
ventilatory support. 
The goals of mechanical ventilation of acute severely brain injured patients are to improve 
gas exchange, to minimize intrathoracic pressure, to reduce the work of breathing and to 
avoid complications. These patients are also in the risk of developing neurogenic pulmonary 
edema, aspiration of oropharyngeal contents, pneumonia, and atelectasis. 
Criteria for starting mechanical ventilation are difficult to define and the decision is made 
clinically. It is decided according to respiratory status. 
Neurologic indications 
 Altered level of consciousness (GCS <8 ) /airway protection. 
 Brainstem dysfunction. 
 Intracranial hypertension. 
 Anticipated neurologic deterioration. 
Respiratory indications 
 Respiratory rate >35 or <5 breaths/ minute 
 Exhaustion, with laboured pattern of breathing 
 Hypoxia - central cyanosis, SaO2 <90% on oxygen or PaO2 < 8kPa 
 Hypercarbia - PaCO2 > 8kPa 
 Tidal volume < 5ml/kg or Vital capacity <15ml/kg 
 
Activity Score
Eye Opening 
None 1= Even to supra-orbital pressure
To pain pressure 2=Pain from sternum/limb/supra-orbital 
To speech 3=Non-specific response, not necessarily to 
command
Spontaneous 4=Eyes open, not necessarily aware 
Motor Response 
None 1=To any pain; limbs remain flaccid 
Extension 2=Shoulder adducted and shoulder and forearm 
internally rotated
Flexor response 3=Withdrawal response or assumption of 
hemiplegic posture
Withdrawal 4=Arm withdraws to pain, shoulder abducts 
Localizes pain 5=Arm attempts to remove supra-orbital/chest 
pressure 
Obeys commands 6=Follows simple commands
Verbal Response 
None 1=No verbalization of any type
Incomprehensible 2=Moans/groans, no speech
Inappropriate 3=Intelligible, no sustained sentences 
Confused 4=Converses but confused, disoriented 
Oriented 5=Converses and oriented
Table 1. Glascow Coma Scale. 
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Intracranial physiology and mechanical ventilation 
The goals of positive-pressure ventilation (PPV) in patients with multitrauma with head 
trauma are improving oxygenation and controlling arterial CO2 tension to minimise 
intracranial hypertension. PPV increases functional residual capacity (FRC) by improving 
alveolar recruitment, thus optimising oxygenation. 
On the other hand, increased intrathoracic pressure (ITP) increases intracranial pressure 
(ICP) by these mechanisms: 
 Direct transmission of ITP to the intracranial cavity via the neck. 
 Increased ITP decreases venous return to the right atrium, and increases jugular venous 
pressure, thereby increasing cerebral blood volume (CBV) and ICP. 
 Decreased venous return decreases cardiac output and mean arterial pressure (MAP). 
This results in decreased cerebral perfusion pressure (CPP) leading to compensatory 
cerebral vasodilation, increased CBF and potentially increased ICP, if cerebral 
autoregulation is impaired. 
Mechanical ventilatory strategies(2): conventional ventilation 
Current practice guidelines for ventilatory management advocate protective lung strategies 
to prevent volutrauma, barotrauma, atelectrauma and biotrauma (3-5). The principles are to 
use low tidal volumes (Vt) (5-6 ml/kg ideal body weight), maintenance of low mean airway 
pressures ≤ 30 cmH2O, judicious use of positive end-expiratory pressure (PEEP) with ∆ 
pressure ≤ 18 cmH2O, higher respiratory rates and permissive hypercapnia. This is in direct 
conflict with the previous “brain-directed” ventilatory strategies that used Vt of 10 ml/kg, 
high FiO2 and low PEEP or zero end-expiratory pressure. There is proven mortality benefit 
with the use of low Vt, but permissive hypercapnia may precipitate intracranial 
hypertension(3,6,7). Animal studies indicate a higher incidence of severe pulmonary oedema 
and haemorrhage after exposure to injurious ventilation in the presence of brain trauma. 
High Vt independently predicts ALI/ARDS and poor outcome in brain trauma patients(8). 
Haemodynamic fluctuations induced by mechanical ventilation may be detrimental in the 
brain with impaired autoregulation. That's why with starting mechanical ventilation, 
intravascular expansion and vasopressor may be necessary. 
The role of PEEP 
Lung protection strategy permising hypercapnia induces the development of cranial 
hyperemia and hypertension. On the other hand, “aggressive” ventilation with high tidal 
volume may aggravate lung injury and provoke ventilator-associated lung damage(9). 
In mechanical ventilation treatment, PEEP improves oxygenation by recruitment of 
atelectatic alveolar units, improving FRC and preventing atelectrauma. Also it may have 
detrimental neurologic effects in certain clinical circumstances(10). In a recent study in 
patients with traumatic brain injury shows that increasing PEEP up to 15 cm H2O to 
optimize oxygenation has not been associated with reduced cerebral perfusion pressure or 
acute intracranial hypertension (11) 
In normal pulmonary compliance, PEEP is associated with increased ITP, decreased 
right atrial volume, decreased MAP and thus compromised CPP. This situation is not 
similar to non-compliant lungs, where there is a comparatively low ITP transmission to 
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the cranium, therefore lesser effects on cerebral blood flow (CBF) and ICP. CPP may be 
indirectly affected by systemic effects of PEEP, but these effects still remain 
quantitatively modest. PEEP is therefore safe to apply as part of a ventilatory strategy 
to improve oxygenation. 
Alveolar overdistension should be avoided and stable haemodynamic parameters should be 
maintained. Head position also needs attention. At least 30º head elevation promotes 
intracranial venous drainage via anterior neck veins, as well as the vertebral venous system 
- which is not majorly affected by ITP. Jugular veins collapse and act as resistors to some of 
the ITP transmitted. Tight endotracheal tube ties around the neck and extremes of neck 
rotation should be avoided 
The Role of PaCO2 control 
Arterial CO2 tension is a powerful modulator of cerebral vascular calibre, CBF and ICP (12-15.) 
While the mechanisms are incompletely understood, CO2 relaxes pial arterioles by 
interactions between the endothelium, vascular smooth muscle, pericytes, adjacent neurons 
and glial cells. Studies supported that cerebral vessels are sensitive to changes in 
extracellular pH, rather than a direct response to CO2 or bicarbonate. In the limits of 
physiological PaCO2, 20-60 mmHg, the relationship between PaCO2 and CBF is linear. 
Therefore, increased PaCO2 results in vasodilation of cerebral vessels and this leads to 
increase CBF, increase CBV, decrease intracranial compliance and increase ICP. The reverse 
mechanism is also true for low CO2 tension. This has been the reason for inducing 
hyperventilation in the patients with intracranial hypertension, but there is a risk for 
cerebral vasoconstriction precipitating cerebral ischaemia because pericontusional areas are 
sensitive to hyperventilation-induced ischaemia. The Brain Trauma Foundation 
management guidelines do not recommend hyperventilation for initial management of 
raised ICP, unless ICP is unresponsive to first-line therapy or hyperventilation is for very 
brief periods of time. Maintaining normocarbia is recomended. 
Role of brain monitoring during ventilatory support in brain injury 
It is essential to monitor intracranial pressure, CPP, and brain oxygenation during 
ventilatory support in the patients with traumatic brain injury. Brain oxygenation 
monitoring technics are jugular venous saturation monitoring, near-infrared spectroscopy 
and microdialysis catheters. Availability and cost of these devices are limiting factors to 
their use. The studies on brain trauma patients shows that there is no proven mortality 
benefit in continuous ICP monitoring.  
Non-conventional ventilatory strategies 
There are some ventilatory strategies that may be used for proper patients. These are prone 
position, recruitment manouvres, high frequency oscillatory ventilation (HFOV) and newer 
technics like extracorporeal CO2 removal (ECCO2R), pumpless extracorporeal lung assist 
(pECLA) and nitric oxide. 
Prone ventilation(15- 18) 
Benefits are: 
 Recruitment of atelectatic lung units. 
 Improved ventilation-perfusion matching. 
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 Improved drainage of secretions. 
 Even distribution of mechanical ventilatory forces. 
ICP and brain tissue oxygenation (PbtO2) monitoring are recomended. There are conflicting 
results on the effects of prone ventilation on ICP and CPP, but there are clear data on 
benefits for respiratory mechanics and oxygenation. Present studies shows that there is no 
mortality benefit to prone positioning. 
Recruitment manoeuvres 
In neurointensive patients with acute lung injury, achieving the goal of lung protection 
without threatening cerebral perfusion is very difficult. In patients with more refractory 
raised intracranial pressure, the optimal balance between brain and lung may not be well 
established. Multiple strategies are used to recruit atelectatic alveoli and improve 
oxygenation. Among them incremental levels of PEEP and high intermittent tidal volumes 
should require extend brain physiological monitoring. 
High frequency oscillatory ventilation (HFOV) (18,19) 
High frequency oscillatory ventilation (HFOV) forms high mean airway pressure with very 
small Vt of 1-5 ml/kg at a rapid rate. It's aim is to recruit alveoli, while preventing 
overdistension. Some studies have supported that HFOV is safe and effective in preventing 
ventilator-induced lung injury (VILI) and improving oxygenation in severe ARDS. There no 
sufficient studies supporting HFOV for the improvement of intracranial compliance. 
Extracorporeal CO2 removal (ECCO2R) (20) 
Extracorporeal membrane oxygenators have been attempted in brain-injured patients to 
improve oxygenation. By using ECMO increased intracranial pressure may decrease in a 
normal limits and CPP is maintained. But anticoagulation requirement in that technic 
increases the risk of intracranial bleeding. 
Pumpless extracorporeal lung assist (pECLA) (21) 
pECLA has recently been utilised in small case series with promising results. Protective 
respiratory care can be maintained while CO2 removal is optimised. Patients treated by 
pECLA must be hemodynamically stable. So cardiovascular instability and shock are 
contraindications for pECLA. Anticoagulation is as for thrombo prophylaxis in immobilised 
patients. The risk of the device clotting is not entirely eliminated by impregnation with 
anticoagulant in the filter. Vascular injury, exsanguination and limb ischaemia are some of 
the recognised complications. 
Nitric oxide 
Nitric oxide improves oxygenation in ALI/ARDS with no survival benefit. There is potential 
to cause harm. There is no data for its use in ARDS with the patients with brain taruma. 
Weaning (22-30) 
Without resolving underlying pathological condition, weaning must not be thought. With 
prolongation ventilatory support, the respiratory muscles become weaken and atrophy of 
this muscles is inevitable. As a consequence, the duration of weaning period is often related 
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to the duration and mode of ventilation. As possible as using assisted modes of ventilation 
and good nutritional support are essential to prevent atrophy of the respiratory muscles. 
Critical illness polyneuropathy is seen in patients recovering from prolonged critical illness. 
In this condition, there is both respiratory and peripheral muscle weakness, with reduced 
tendon reflexes and sensory abnormalities. There is evidence that long-term administration 
of some aminosteroid muscle relaxants (such as vecuronium) may cause persisting 
paralysis. No absolute treatment is used for it except supportive therapy. 
The plan for disengagement of the patient from mechanical ventilation should be made at 
initiation of ventilation therapy. The recognition of when mechanical ventilatory support 
should be reduced and ultimately discontinued is so important. Appropirate time for 
disengagement from ventilation has the following advantages: 
 Decreased airway injury 
 Decreased risk of VILI. 
 Decreased risk of VAP. 
 Decreased sedation requirements. 
 Decreased delirium. 
 Shortened ICU length of stay. 
 Assessment for extubation criteria: 
 Respiratory criteria. 
 Haemodynamic criteria. 
 Neurologic criteria. This includes stable neurological status, ICP ≤ 20 mmHg, CPP ≥ 60 
mmHg. 
Premature weaning and extubation may cause respiratory muscle fatigue, gas exchange 
failure and loss of airway protection. 
There is clear benefit to weaning according to protocol. There should be frequent assessment 
of ventilatory support requirement and re-evaluation of factors contributing to ventilator 
dependence before ventilation is discontinued. 
Indications for weaning 
 Improving of underlying illness 
 Respiratory function: 
Respiratory rate < 35 breaths/minute 
FiO2 < 0.5, SaO2 > 90%, PEEP <10 cmH2O 
Tidal volume > 5ml/kg 
Vital capacity > 10 ml/kg 
Minute volume < 10 l/min 
 Absence of infection or fever 
 Cardiovascular stability, optimal fluid balance and electrolyte replacement 
Prior to trial of weaning, there should be no residual neuromuscular blockade and sedation 
should be stoped or decreased in appropirate level so that the patient must be awake, 
cooperative and in a semirecumbent position. Weaning is likely to fail if the patient is 
confused, agitated or unable to cough. 
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Modes of weaning 
There are several different approaches for the weaning that are not superior to others. 
 Unsupported spontaneous breathing trials. The machine support is withdrawn and a T-
Piece (or CPAP) circuit can be attached intermittently for increasing periods of time, 
thereby allowing the patient to gradually take over the work of breathing with 
shortening rest periods back on the ventilator. 
 Intermittent mandatory ventilation (IMV) weaning. The ventilator delivers a preset 
minimum minute volume which is gradually decreased as the patient takes over more 
of the respiratory workload. The decreasing ventilator breaths are synchronised to the 
patient's own inspiratory efforts (SIMV). 
 Pressure support weaning. In this mode, the patient initiates all breaths and these are 
'boosted' by the ventilator. This weaning method involves gradually reducing the level 
of pressure support, thus making the patient responsible for an increasing amount of 
ventilation. Once the level of pressure support is low (5-10 cmH2O above PEEP), a trial 
of T-Piece or CPAP weaning should be commenced. 
Failure to wean 
During the weaning process, the patient should be observed for early indications of fatigue 
or failure to wean. These signs include distress, increasing respiratory rate, falling tidal 
volume and haemodynamic compromise, particularly tachycardia and hypertension. At this 
point it may be necessary to increase the level of respiratory support as, once exhausted, 
respiratory muscles may take many hours to recover.  
It is sensible to start the weaning process in the morning to allow close monitoring of the 
patient throughout the day. In prolonged weaning, it is common practice to increase 
ventilatory support overnight to allow adequate rest for the patient. 
Tracheostomy in the intensive care unit (31-33) 
The commonest indication of tracheostomy in an ICU setting is to facilitate prolonged 
artificial ventilation and the subsequent weaning process. Tracheostomy allows a reduction 
in sedation and thus increased cooperation to the weaning process. It also allows effective 
tracheobronchial suction in patients who are unable to clear pulmonary secretions either 
due to excessive secretion production or due to weakness following critical illness. 
Tracheostomy can be performed as a formal surgical procedure in theatre or at the bedside 
in the intensive care unit using a percutaneous method. Tracheostomy placement leads to 
earlier liberation from mechanical ventilation, but without any mortality benefit or effect on 
pulmonary infection rates. 
Other indications for tracheostomy are to bypass an upper airway obstruction, protect the 
lungs from soiling if the laryngopharygeal reflexes are depressed or as part of a surgical or 
anaesthetic technique eg larygectomy. 
Advantages of tracheostomy is summerized as decreased risk of self-extubation; decreased 
sinusitis; decreased airway resistance, dead space and breathing work ;better tolerance; less 
sedative requirements; potentially-reduced duration of mechanical ventilation. 
Risks of tracheostomy is summerized as surgical site infection, airway haemorrhage, 
pneumothorax, oesophageal perforation. 
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Sedation in the Neuro-ICU(34-67) 
Sedation is the important factor in comfort of brain trauma patients. Insuffient sedation 
causes hypertension, tachycardia, hypoxia, hypercapnia and uncomfortable with ventilator. 
On the other hand excess sedation causes hypotansion, bradycardia, coma, respiratory 
depresion, ileus, renal insufficiency, veinous stasis and immunosupression. 
For the patients in the critical care unit firstly nonpharmacological method should be 
experinced for sedation. The patients should be frequently oriented. Sleep-awake cycling, 
proper enveriomental temperature, control of the noise aroused from alarms must be 
arranged. 
Calling the family members, the relexing exercises, musical therapy, masaj and sitting 
exercises are important in control of anxiety and ajitation of patients. 
Safe and effective management of the pain and anxiety needs a delicate balance for 
analgesia and sedation protocols while managing delirium status.  
The weaning of patients from mechanical ventilation is often hampered by the sedation that 
they receive. Additionally, coordinated daily interruption of sedative infusions with 
objective re-titration in critically ill patients has been shown to decrease the durations of 
mechanical ventilation and length of ICU stay. 
Consequences of agitation include self-extubation, removal of IV catheters, dyssynchrony 
with mechanical ventilation, and, perhaps, a long-term risk of psychiatric problems, such 
as delirium and posttraumatic stress disorder can be prevented by a proper sedation. 
Prolonged and excessive sedation are problematic too, interfering with weaning from 
mechanical ventilation and leading to increased rates of nosocomial pneumonia, 
prolonged ICU stays, and difficulty identifying new problems, such as myocardial 
infarction or stroke. 
Sedation Indications in the Neuro-ICU 
 Patient comfort 
 Decreases anxiety and agitation 
 Relieve fear 
 Risk of self-injury or injury of others 
 Withdrawal from alcohol or drugs 
 Risk of self-extubation or removal of invasive monitors 
 Suppreses stres response  
 Increases the tolerance of ventilatory support 
 Facilitates the cares like aspiration, invasive prosedures and dressing the wound 
 Control of pain 
 Facilitate mechanical ventilation 
 Reduce oxygen extraction/ utilization in ARDS and Sepsis 
 Brain protection (seizure control, decrease cerebral metabolism , control ICP) 
 Blunting adverse outcome  
 Provide hemodynamic stability; protection against myocardial ischemia 
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 Amnesia during paralysis with muscle relaxants 
 During interventions (line insertion, tracheostomy) 
 To prevent movement (during imaging and transfering of the patient) 
 Facilitate sleep 
 Facilitate nursing management 
Properties of an ideal agent for neurointensive care sedation: 
 Rapid onset and rapid recovery so that a neurologic evaluation can be conducted 
 Predictable clearance independent of end-organ function, avoiding the problem of drug 
accumulation 
 Easily titrated to achieve adequate levels of sedation 
 Reduces intracranial pressure by cerebral blood volume reduction or cerebral 
vasoconstriction  
 Reduces cerebral blood flow and cerebral metabolic rate of oxygen consumption, 
maintaining their coupling 
 Maintains cerebral autoregulation 
 Permits normal cerebral vascular reactivity to changes in arterial carbon dioxide tension 
 Minimal cardiovascular depressant effects 
 Easy control respiratory side-effects 
 Inexpensive 
 Adapted with permission. 
 Both sedative and analgesic 
 Lack of respiratory depression 
 No tolerance over time 
 Inactive or non harmful metabolites 
 No interactions with other ICU drug 
 Rapid onset and rapid recovery so that a neurologic evaluation can be conducted 
General expectational situations: 
 Equipment and personnel to intubate and mechanically ventilate must be readily 
available 
 Decreased level-of-consciousness or obtundation 
 Poor airway protection 
 Respiratory depression, hypercarbia, and increased intracranial pressure (ICP) 
 Impairment of neurological exam 
 Hemodynamic instability 
Sedation should be performed according to protocols standarized with scales. For this 
reason Ramsay Sedation Scale (RSS), Riker Sedation-Agitation Scale (SAS) and Richmond 
Agitation-Sedation Score (RASS) are used for planing treatment. For many years, the 
Ramsay Sedation Scale was the most commonly used tool to monitor sedation in the ICU. 
However, it cannot distinguish different levels of agitation, making it less useful than other 
available scales. Currently, two of the most commonly used techniques are the Riker 
Sedation-Agitation Scale (SAS) and the Richmond Agitation-Sedation Score (RASS). 
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Score Term Descriptor 
1. Unarousable – Minimal or no response to noxious stimuli, does not communicate or 
follow commands 
2. Very Sedated – Arouses to physical stimuli but does not communicate or follow 
commands, may move spontaneously 
3. Sedated – Difficult to arouse, awakens to verbal stimuli or gently shaking, but drifts off 
again, follow simple commands 
4. Calm and Cooperative – Calm, awakens easily, follows commands 
5. Agitated – Anxious or mildly agitated, attempting to sit up, calms down to verbal 
stimuli 
6. Very Agitated – Does not calm despite frequent verbal reminding of limits, biting ET 
7. Dangerous Agitation – Pulling ET, trying to remove catheters, climbing over bedrails, 
striking at staff, thrashing side to side 
Guidelines for SAS Assessment  
1. Agitated patients are scored by their most severe degree of agitation, as described. 
2. If patient is awake or awakens easily to voice (“awaken” means responds with voice or 
head shaking to a question or follows commands), that is a SAS 4 (same as calm and 
appropriate might even be napping). 
3. If more stimuli such as shaking is required but patient eventually does awaken, that is 
a SAS 3. 
4. If patient arouses to stronger physical stimuli (may be noxious) but never awakens to 
the point of responding yes/no or following commands, that is a SAS 2. 
5. Little or no response to noxious physical stimuli is a SAS 
6. This helps separate sedated patients into those you can eventually awaken (SAS 3), 
those you can not awaken, but can arouse (SAS 2), and those you can not arouse (SAS 1). 
 
Table 2. Riker Sedation-Agitation Scale (SAS) (SAS Target Sedation = 3 to 4). 
 
 
Score Description 
+4Combative Overtly combative, violent, immediate danger to staff 
 +3 Very Agitated Pulls or removes tube(s) or catheter(s),aggressive 
 +2 Agitated Frequent non-purposeful movement, fights ventilator 
 +1 Restless Anxious but movements not aggressive vigorous 
 0 Alert and Calm  
 -1 Drowsy Not fully alert, but has sustained awakening 
(>10 seconds) (eye-opening/eye contact) to voice  
 -2 Light Sedation Briefly awakens with eye contact to voice (<10 seconds) 
 -3 Moderate Sedation Movement or eye opening to voice (but no eye contact) 
 -4 Deep Sedation No response to voice, but movement or eye opening to 
physical stimulation 
 -5 Unarousable No response to voice or physical stimulation 
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Procedure for RASS Assessment: The basis of the RASS assessment is to see what amount 
of stimulation is necessary to evoke a respons and evaluate sedation. 
 Observe patient. 
a. Patient is alert, restless, or agitated. (Score 0 to +4) 
 If not alert, state patient’s name and say “open eyes and look (speaker).” 
b. Patient awakens with sustained eye opening and eye contact (Score –1) 
c. Patient awakens with eye opening and eye contact, but not sustained (Score –2) 
d. Patient has any movement in response to voice but no eye contact (Score –3) 
 When no response to verbal stimulation, physically stimulatepatient by shaking 
shoulder and/or rubbing sternum. 
e. Patient has any movement to physical stimulation (Score –4) 
f. Patient has no response to any stimulation (Score –5). 
Table 3. Richmond Agitation Sedation Scale (RASS) ( RASS Target Sedation = 0 to -3). 
Even if the sedative strategy in the NICU shares the same general aims as general intensive 
care, the characteristics of the patients in the NICU present other unique challenges and 
specific indications, including intracranial pressure control, cerebral oxygen consumption 
and seizure reduction . Analgesic and sedative agents are used both to prevent undesirable 
increases in intracranial pressure and to reduce cerebral metabolic requirements. 
Intracranial pressure control cerebral autoregulation may be impaired in the traumatic brain 
injury. Therefore, agitation and associated blood pressure elevations directly determine 
intracranial pressure surges. Moreover, severe agitation increases intrathoracic pressure, 
reducing jugular venous outflow and increases cerebral metabolism with concomitantly 
increased cerebral blood flow (CBF). These potentially deleterious phenomena can lead to 
increase in intracranial pressure. This can trigger an additional cerebral vasodilator cascade, 
as cerebral perfusion pressure (CPP) is reduced. 
Sedatives decrease the cerebral metabolic rate of oxygen consumption (CMRO2), and 
because the coupling of CBF and CMRO2 is usually maintained with these agents, CBF is 
reduced by increasing cerebral vascular resistance. The reduction in CBF results in a 
reduction of cerebral blood volume and, consequently, a decrease in intracranial pressure. In 
order to maintain adequate oxygen availability and energy production at the cellular level, 
treatment is directed to increase oxygen delivery by optimizing systemic hemodynamics 
and reduce cerebral metabolic demand. Sedative drugs confer a protective effect by 
reducing oxygen demand and increasing oxygen delivery (through improvement of central 
perfusion pressure and by inhibiting deleterious pathologic intracellular processes). The 
pharmacologic reduction in CMRO2 depresses either the basal or the activation components 
of cerebral metabolism. The metabolic suppression is dose dependent until the 
electroencephalogram becomes isoelectric. Beyond this level, no further suppression of 
cerebral oxygen consumption or blood flow occurs because energy expenditure, associated 
with electrophysiologic activity, has been reduced to close to zero, and the minimal 
consumption for cellular homeostasis persists unchanged. 
There is no appropirate ratio for seizure activity in patients with brain trauma, seizures are a 
frequent complication in the NICU. Sedation appears to be an attractive option in reducing 
seizures in the NICU. Benzodiazepines increase the seizure threshold and are useful 
anticonvulsants. There are conflicting data on propofol, and, consequently, its ability to 
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protect against seizures is less certain. Pharmacologic properties rapid onset and rapid 
recovery of hypnosis are the most important pharmacokinetic properties to consider when 
comparing different hypnotic alternatives. 
The drug used for sedation in intensive care summarized in table below. 
 
 
 
 
 
 
NR: Not recommended 
Table 4. Pharmacokinetic parameters, dosing, and cost of sedative and analgesic agents. 
For patients that are mechanically ventilated for three days or less, short acting agents 
should be used such as Propofol or Midazolam. For longer periods of mechanical 
ventilation, longer acting agents such as Lorazepam should be used. Patients that have been 
ventilated for long periods using the long acting agent Lorazepam may need to be switched 
to a shorter acting agent such as Propofol for optimal weaning purposes. 
 
 
 
 
Rapid onset             
Fast recovery           
Easily titrated          
ICP reduction          
CBF reduction         
CMRO2 reduction  
MAP                       
Propofol
+++ 
+++ 
+++ 
ŅŅ 
ŅŅ 
ŅŅ 
ŅŅ 
Midazolam
+++ 
++ 
++ 
  Ņ 
ŅŅ 
Ņ 
   Ņ 
Lorazepam
+ 
+ 
+ 
Ņ 
Ņ 
Ņ 
     Ņ 
Fentanyl 
+++ 
++ 
++ 
ņ/Ņ 
ņ 
Ņ 
    Ņ 
Remifentanyl 
+++ 
+++ 
+++ 
ņ/Ņ 
ņ 
  Ņ 
ŅŅ 
 
↑, modest increase; ↑↑, pronounced increase; ņ, no clear effect; Ņ, modest decrease; ŅŅ, pronounced 
decrease; +++, very favorable; ++, favorable; +, not favorable; CBF, cerebral blood flow; CMRO2, 
cerebral metabolic rate of oxygen consumption; ICP, intracranial pressure; MAP, mean arterial 
pressure. 
 
 
Table 5. Cerebral and systemic characteristics of the available molecules. 
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Barbiturate, benzodiazepins, propofol and narcotics are all used as a sedative agent. 
Propofol is very lipid soluble, has a large volume of distribution, and can be given for 
prolonged periods of time without significant changes in its pharmacokinetic profile. 
Because propofol has no active metabolites, the termination of its clinical effect is dependent 
solely on redistribution to peripheral fat tissue stores. When the infusion is discontinued, the 
fat tissue stores redistribute. Because of its pharmacokinetics and specific effects on cerebral 
hemodynamic variables, preserving autoregulation and vasoreactivity to carbon dioxide, 
propofol approximates the ideal sedative. Intravenous bolus administration produces a 
dose-dependent, coupled decrease in CBF and CMRO2 similar to that described after 
barbiturate administration. The effects on CBF are probably secondary to a reduction in 
CMRO2. A strong linear correlation between CBF and CMRO2 has been demonstrated. The 
major cardiovascular effect of propofol is a profound decrease in mean arterial pressure, 
resulting from a decrease in systemic vascular resistance, cardiac contractility, and preload. 
A bolus dose of 2 to 2.5 mg/kg propofol results in a 25 to 40% reduction in systolic blood 
pressure. This potent effect on mean arterial pressure may affect CPP by one of two 
mechanisms. If autoregulation is intact, a reduction in mean arterial pressure will produce 
reflex cerebral vasodilatation and a possible increase in intracranial pressure. Alternatively, 
if autoregulation is impaied hypotension may produce a critical decrease in CPP and CBF. 
The risk of hypotension is greatest in the presence of hypovolemia. 
Evaluations of the effects of benzodiazepines on cerebral physiology have involved 
primarily diazepam and midazolam. Both cause dose-dependent decreases in CMRO2 and 
CBF, and by increasing cerebral vascular resistance, decreases in intracranial pressure have 
been observed. Usually CPP is not compromised. Moreover, a “ceiling effect” in CBF and 
CMRO2 reduction has been described, suggesting a saturation of the benzodiazepine 
receptors. It appears that benzodiazepines are safe to administer to patients with intracranial 
hypertension without respiratory depression and associated increases in arterial carbon 
dioxide tension. 
The cerebral physiologic effects of opioids are controversial. Morphine-related increases in 
CBF, as described in early reports, were probably secondary to an increaseing arterial 
carbon dioxide tension resulting from respiratory depression. In general, opioids slightly 
reduce CMRO2, CBF, and intracranial pressure, as long as normocapnia is maintained by 
mechanical ventilation. Opioids can produce short-lasting, mild decreases in mean arterial 
pressure and then, subsequently, can produce decreases in CPP. Furthermore, remifentanyl 
may cause decreases in both cerebral metabolic rate and intracranial pressure, with minimal 
changes in CPP and cerebral blood flow. Opioids lead to dose-dependent, centrally 
mediated respiratory depression. The carbon dioxide response curve is shifted to the right, 
and the ventilatory response to hypoxia is obliterated. For this reason, in spontaneously 
ventilating NICU patients, if opioids are administered, strict end-tidal carbon dioxide 
monitoring or frequent blood gas analysis must be implemented to identify rapid onset of 
respiratory depression. When opioids and benzodiazepines are administered concomitantly, 
they may exhibit a synergistic effect on hemodynamics. The reasons for this synergy are not 
entirely clear. 
Hypnotics can decrease mean arterial blood pressure by both cardiac depression and 
peripheral vasodilatation. The decrease in blood pressure can cause an increase in 
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intracranial pressure as a result of autoregulatory compensation (vasodilatory cascade) and 
consequently, can cause a reduction in CPP. The hemodynamic effects are usually dose 
dependent. Therefore, to avoid, or at least to limit, decreases in blood pressure, the patient 
should be euvolemic before the infusion is started, and slow boluses or continuous infusions 
are preferred. 
Because no single drug can achieve all of the requirements for sedation and analgesia in the 
ICU, use of a combination of drugs, each titrated to specific end points, is a more effective 
strategy. This allows lower doses of individual drugs and reduces the problems of drug 
accumulation. In the acute phase (ie, first 48–72 hours or when intracranial hypertension is 
not controlled), a continuous infusion of a combination of propofol (1.5–6 mg/kg/h) and 
fentanyl (0.5–1.5 µg/kg/h) should be initiated. 
In the subacute phase (ie, after 72 hours or when intracranial pressure is normalized), 
intermittent infusion of lorazepam (0.05 mg/kg every 2–6 h) should be initiated. 
It is essential to contiue sedation until ventilatory support is required, and then sedation is 
stoped step by step to prevent withdrawal symptoms in 24 to 48 hours. No neuromuscular 
blocking drugs are routinely added, except in cases of severe, uncontrollable intracranial 
hypertension. 
Neuromuscular blockers in the Neuro-ICU (68-71) 
The routine use of neuromuscular blockers varies between centres. The routine use of 
muscle relaxants should be avoided, they can be useful to prevent peaks in ICP induced 
by the patient coughing or “straining” or in the face of patient-ventilator dysynchrony. 
However, muscle paralysis makes it clinically impossible to recognise and treat 
seizures. Prolonged administration of neuromuscular blockers by continuous infusion 
can also lead to significant long-term problems, such as critical illness polyneuropathy 
and myopathy. 
Neuromuscular blockers indications 
 Facilitation of intubation 
 Facilitate mechanical ventilation 
 To eliminate spontaneous breathing and promote mechanical ventilation 
 During interventions (line insertion, tracheostomy) 
 To prevent movement (during imaging and to permit transfer of the patient) 
 Severe refractory intracranial hypertension 
 Severe pulmonary disease with inability to mechanically ventilated 
 Cause a pharmacologic restraint so patients do not harm themselves 
General Precautions 
 Patient must be intubated for mechanically ventilated 
 Transient increase in ICP with depolarizing blockade (succinylcholine) 
 Unexpected prolongation of neuromuscular blockade (e.g.,enzyme deficiencies, hepatic 
or renal dysfunction) 
 Complete loss of neurological examination 
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Agent Onset of action Duration of action ED90-95* (mg/kg) 
 
Agent Onset of action 
Duration  
of action 
ED90-95* (mg/kg) 
 Short Acting   
 
Mivacurium 
(Mivacron) 
2.5 min 15 - 20 min 0.07 
Rapacuronium 
(Raplon) 
Mean: 90 
seconds 
(35 - 219 sec) 
Mean: 15 min 
(6 - 30 min) 
1.03 
Rocuronium 
(Zemeron) 
1 - 3 min 
31 min 
(15 - 85 min) 
0.3 
Succinylcholine 30 - 60 seconds 5 - 8 min 0.3 
Intermediate acting 
Atracurium 
(Tracrium) 
2.5 - 5 min 20 - 45 min 0.2 
Cisatracurium 
(Nimbex) 
2 - 3 min 30 - 40 min 0.05 
Pancuronium 
(Pavulon) 
2 - 3 min 60 - 90 min 0.06 
Vecuronium 
(Norcuron) 
2 - 3 min 25 - 40 min 0.05 
Long Acting 
Doxacurium 
(Nuromax) 
6 min 
(2.5 - 13) 
100 min 
(39 - 232) 
0.025 
Pipecuronium 
(Arduan) 
2.5 - 5 min 
75 min 
(35 - 175) 
0.07 
Tubocurarine 3 - 5 min 70 - 90 min 0.05 
 
ED90-95 = Dose required to produce 90-95% suppression of muscle response 
Table 6. Neuromuscular Blocking Agents. 
Atracurium: initially 0.4 -0.5 mg/kg IV bolus, Maintenance infusion rates of 5 to 9 
mcg/kg/min are usually adequate (Range:2 to 15mcg/kg/min). Toxic metabolite 
(laudanosine) may accumulate in renal failure 
Doxacurium: initially, 0.05 mg/kg -0.08 mg/kg IV bolus, Maintenance, 0.005 mg/kg and 
0.01 mg/kg IV to provide neuromuscular blockage for an average of 30 min and 45 min, 
respectively.  
Rocuronium: initially, 0.6-1.2 mg/kg IV bolus. Maintenance, 0.1-0.2 mg/kg IV repeated as 
needed. Maintenance (continuous IV infusion): 0.01-0.012 mg/kg/minute. 
Pancuronium: initially 0.1 to 0.2 mg/kg (usually 0.1) bolus, followed by 1 to 1.7 
mcg/kg/min or 0.06 to 0.1 mg/kg/hr 
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Vecuronium: Initially 0.08 to 0.1 mg/kg IV bolus. (Higher initial doses-up to 0.3 mg/kg-may 
be used for rapid onset. Continuous infusion: 1 mcg/kg/min infusion, usual range: 0.8 to 
1.2 mcg/kg/min). 
Succinylcholine: Initially 0.3–1.1 mg/kg, bolus Infusion is 2.5–4.3 mg/min (cause refractory 
intracranial hypertension Succinylcholine should be avoided due to increased ICP) 
Nutrition 
Nutrition could also have an impact on the posttraumatic stress response, which is 
associated with adverse outcomes from TBI. The posttraumatic stress response is 
charaterized by increased blood levels of glucose, lactate, catecholamines, and cortisol. 
Nutrition support should be initiated as soon as possible following the head injury. 
Adequate nutrition is to provide the body healing. Early enteral nutrition (EN) support has 
been shown to attenuate the catabolic response and improve immune function and is 
associated with improved neurologic outcome(73,74) .If the digestive tract is functional, 
enteral nutrition, or nutrition given via a tube placed into the stomach, is the preferred 
route. Parenteral nutrition (PN) should be reserved for those patients with impaired 
gastrointestinal function or those who cannot meet their nutritional needs via EN alone. 
The goal of nutritional support in patients who are critically ill is to provide protein and 
caloric replacement while attenuating a negative nitrogen balance. Incidence of malnutrition 
in hospitalized patients ranges between 30% to 55%. Delaying in the initiation of nutritional 
support may result in muscle and gastrointestinal atrophy, inability of weaning from 
ventilatory support, heart failure, impaired immunity, increase in the incidence of sepsis, 
length of hospital stay, morbidity and mortality and all of these resulte increase in costs (72). 
At the begining, all patients admitted to the critical care unit should be screened for risk or 
presence of malnutrition. Critically ill patients with neurologic impairment often require 
specialized nutrition support because of needing intubation, dysphagia, or altered mental 
status. 
The provision of adequate nutritional support is an essential component of caring the 
critically ill patient. During starvation, homeostatic mechanisms are designed to burn fat 
rather than protein as an energy source until the fat stores are significantly depleted. 
Especially in the begining of the infection, a catabolic state causing significant protein loss 
progresses. Plasma and urine levels of catecholamines and cortisol are elevated. 
Hyperglycaemia is frequently seen and causes ketone production and lactic acid production 
leading acidosis in brain cells. The studies show that the severity and duration of 
hyperglycaemia following head injury correlate with longer term outcome. 
Enteral nutrition should be preferred in the critically ill patients(75,76). This can be achieved 
by either nasal tube feeding or via a percutaneous gastrostomy (PEG) if prolonged feeding is 
envisaged. Standard enteral feeding regiments aim to provide 1500–2500 kcal in 24 hours 
with 70 g protein in a volume of 1.5–2 L. 
A patient may require more calories for healing for the TBI. Patients with a GCS of 8 to 12 
will require approximately 30 to 35 calories per kilogram of body weight per day. Patients 
with a GCS of 6 to 7 require 40 to 50 calories per kilogram of body weight per day. 
The main goal of nutrition should be preserve muscle mass, and provide adequate fluids 
and strict electrolyte and glucose monitoring should be recommended. 
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It is prudent to consider postpyloric feeding in patient with neurological catastrophies, 
because gastric atony increases the risk of aspiration. Enteral feeding should be preferably 
done by continuous infusion with a volumetric pump. 
In the average patient in the intensive care unit who has no contraindications to EN or PN, 
the choice of route for nutritional support may be influenced by several factors. Because EN 
and PN are associated with risks and benefits(77,78) 
Advantages associated with enteral rather than parenteral nutrition include: 
 Maintenance of mucosal integrity and prevention of villous atrophy 
 Reduced infection rate 
 Absence of requirement for central venous line 
 Better maintenance of fluid balance 
 Reduced cost 
Contraindications to enteral feeding are few, particularly in the patient with isolated 
intracranial pathology, but include abdominal sepsis, obstruction, acut malabsorption and 
inflammatory syndromes and enteric fistulae. Only a short segment of small intestine (30 
cm) is required for adequate absorption since hypertrophy will occur in response to lumenal 
nutrients. Neither bowel sounds nor flatus are required for successful enteral feeding. 
Enteral feeding should be started if gastric aspirates are less than 400 ml/day and there are 
no obvious contraindications. Commence with standard enteral feed at 25 ml/h, increasing 
the rate every 12 hours until 100 ml/h is achieved. Aspirate residual volume and rest for 1 
hour in every 6 hours of feeding, and rest continuously for 8 hours overnight. 
Complications of enteral feeding (79).: 
 Large residual gastric volumes. 
 Regurgitation and aspiration. 
 Diarrhoea. 
 Ulceration of nares. 
 Contamination of feed (rare). 
Gastric atony and delayed emptying may be seen during enteral feeding. For treating this 
unwanted result pro-kinetic agents can be used. Also nasojejunal tube bypassing pylorus 
should be inserted. The passage of nasal feeding tubes should be avoided in patients with 
facial injuries and basal skull fracture. Instate oragastric replacement should be used. 
Diarrhoea also may be seen during enteral feeding and may resolve with using a different 
formula of feed. But persistent diarrhoea should be thought infection with Clostridium 
difficile , particularly in patients receiving multiple antibiotics. A specimen should always 
be sent for microbiological culture. 
Total parenteral nutrision (TPN) is prefered especialy enteral nutrision is imposible(80). 
Protein calorie requirements are more easily met by parenteral nutrition comparing enteral 
nutrition. Excessive calorie intake, particularly consisting excessive carbohydrate increases 
oxygen consumption, carbon dioxide production, the respiratory quotient (RQ) and 
lipogenesis. 
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The calorie:nitrogen ratio for TPN should be 150:1 and it must be contain lipid, 
carbonhyrates, amino acids, electrolytes, trace elements and vitamins as much as needed. 
Lipids are essential for cell wall integrity, prostaglandin synthesis and the action of fat-
soluble vitamins, but should provide no more than 33% of the energy requirements. 
Intralipid, mixture of refined olive oil (approximately 80%) and refined soya oil 
(approximately 20%) ( which may rarely cause severe hypersensitivity reactions), is an 
isotonic emulsion of soyabean oil with egg phosphatides and lecithin. The particle size of 
the emulsion is similar to a chylomicron, and the lipidis handled in a similar manner. The 
energy yield from fat is 9 cal/g, but the presence of the egg phosphatides increase the caloric 
value of intralipid to 11 cal/g. The lipid load should be decreased in the presence of 
sedation with propofol, severe jaundice ,severe hypoxamia, thrombocytopaenia and 
hypothermia . 
Carbohydrate should be consist of two-thirds of the energy requirement and is in the form 
of glucose having 4cal/g energy. An insulin sliding scale will frequently be required to 
tightly control plasma glucose levels. 
Protein is usually omitted from caloric calculations. A wide range of amino acids are 
supplied as the L-isomer in commercial preparations. Protein requirements increase in 
sepsis and burns and are 12–17 g nitrogen/day (1 g nitrogen=6.25 g protein). 
Daily electrolyte requirements of sodium, potassium, calcium, phosphate, magnesium and 
chloride should be met by TPN. Trace elements essential for homeostasis include zinc, 
copper, manganese, iron, cobalt, chromium, selenium, molybdenum and iodine. 
Commercially prepared vitamin supplements contain most water-soluble and fat-soluble 
vitamins (A, D and E) with the exception of folic acid, vitamin B12 and vitamin K (fat-
soluble). 
 
Schedule Enteral Parenteral 
Baseline 
Electrolytes, BUN, Cr, Ca, Mg, 
PO4, glucose, albumin 
Electrolytes, BUN, Cr, Ca, Mg, 
PO4, glucose, liver function 
tests, triglycerides, 
cholesterol, albumin 
Daily Intake and output, weight Intake and output, weight 
Daily until stable; then 2 to 3 
times/week 
Electrolytes, BUN, Cr, glucose Electrolytes, BUN, Cr, glucose 
Every other day until stable; 
then 1 to 2 times/week 
Ca, Mg, PO4 Ca, Mg, PO4 
Every 10-14 days Albumin 
Liver function tests, albumin, 
triglycerides 
Weekly PT, prealbumin PT, prealbumin 
BUN, blood urea nitrogen; PT, prothrombin time; Cr, creatinine; PO4, phosphate 
Table 7. Recommended monitoring guidelines for enteral and parental nutrition. 
Increasingly, hospital pharmacies are supplying pre-mixed ‘big bag’ TPN containing the 
complete 24-hour nutritional requirements. 
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While receiving enteral or parenteral nutrition, the patient must be monitored for changes in 
body composition, blood chemistry, blood glucose, triglycerides, and protein synthesis. 
Electrolytes (Na, K, Cl, Mg, Phosphate, and Ca) and markers of renal function (blood urea 
nitrogen and creatinine) should be monitored routinely. Daily weight and the total volume 
of the patient's intake and output need to be monitored in addition to assessing other 
markers of hydration and volume status. 
Management and treatment of intracranial hypertension 
The principle focus of critical care management for traumatic brain is to limit secondary 
brain injury (SBI). On admission to the NICU, all patients after trauma are at risk of 
increasing ICP, and standard systemic monitoring; pulse oximetry, invasive arterial blood 
pressure with regular analyses of arterial blood gases and blood glucose and central venous 
access with central venous pressure monitoring must be established. End-tidal carbon 
dioxide monitoring is invaluable in this group of patients because it enables early correction 
of hypercapnia-induced rises. 
For the treatment and prevention of SBI, using a neuroprotective strategy to maintain 
cerebral perfusion and maintaining intracranial pressure within normal limits are important. 
Beside this optimizing oxygenation and blood pressure are needed and temperature, 
glucose, seizures, and other potential secondary brain insults management are essential. 
If GCS of the patients equal and below the 8, there are clinical symptoms like unilateral or 
bilaterally fixed and dilated pupils suggesting possible impending herniation from elevated 
ICP and/or decorticate or decerebrate posturing, bradycardia, hypertension, and respiratory 
depression progress, the treatment of head elevation, hyperventilation, and osmotic therapy 
(mannitol 1 g/kg iv) is planed urgently. With the treatment neuroimaging and other 
assessments are organized. The evaluation and management of increased ICP are discussed 
in detail below. 
In traumatic brain injury, ICP and low CPP cause mass effect in the brain and is associated 
with more severe symptoms and more abrupt onset and poor outcome. The increased ICP is 
caused by increases in tissue volume, cerebral blood volume, or cerebrospinal fluid (CSF) 
volume. The pathophysiology and management of increased ICP is based on the Monro-
Kellie doctrine. 
Cerebral blood flow is maintained through adequate CPP, which is determined by the mean 
systemic arterial pressure minus intracranial pressure (CPP = MAP – ICP). Normal CPP 
values 80 mm Hg for adults, CPP > 50–60 mm Hg for children and CPP > 40–50 mm Hg for 
infants/toddlers. 
If the CPP reduces below the value of 70 mmHg, it assosiated with high mortality and poor 
outcome(81-83) Especially the value reduces to less than 50 mmHg, metabolic evidence of 
ischaemia, reduced electrical activity and, ultimately, brain death are expected. 
Normal values of ICP are within the range of 10 to 15 mm Hg for adults and older children, 
3 to 7 mm Hg for young children, and 1.5 to 6 mm Hg for term infants( 84). Intracranial 
hypertension (ICH) is defined when the ICP values ebow 20 mm Hg. The values greater 
than 20 to 25 mm Hg require treatment in most circumstances. Sustained values of greater 
than 40 mm Hg indicate severe, life-threatening intracranial hypertension(76). During 
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intracranial hypertension, systemic hypotension or relative hypotension (insufficient to 
maintain adequate CPP due to increased ICP) lead to poor cerebral perfusion and ischemic 
insults and worse outcomes(81,85) and treatment is recommended (81,85,86) . 
Sustained intracranial hypertension has a negative effect on cerebral blood flow and cerebral 
perfusion pressure and can cause direct compression of vital cerebral structures and lead to 
herniation. Appropriate management of intracranial hypertension begins with stabilization 
of the patient and simultaneous assessment of the level of sensorium and the cause of it. 
Stabilization is initiated with securing the airway, ventilation and circulation(87). The 
management of the patient involves the maintenance of an adequate CPP, prevention of 
intracranial hypertension and optimization of oxygen delivery. In patients with severe 
coma, signs of herniation or acutely elevated intracranial pressure, treatment should be 
started prior to plan imaging technics or invasive monitoring. 
Indications for ICP monitoring, varing from unit to unit, may include traumatic brain injury, 
anoxic-ischaemic brain injury, intracerebral and subarachnoid haemorrhage, hydrocephalus, 
brain oedema after large strokes, hypoxic brain injury, central nervous system infections or 
fulminant hepatic failure(83,85). 
The primary goals of ICP monitoring are identification of intracranial pressure trends and 
evaluation of therapeutic interventions. Intracranial hypertension compromises the 
relationship between systemic blood pressure and the resistance that must be overcome to 
accomplish cerebral perfusion. When cerebral perfusion pressure (CPP) falls below 50 mm 
Hg, secondary brain ischemia, herniation, and, ultimately, brain death occur. ICP 
monitoring allows for early detection of intracranial hypertension and subsequent 
aggressive management. 
ICP monitoring helps the earlier detection of intracranial mass lesions and can limit the 
indiscriminate use of therapies to control ICP which themselves can be potentially harmful. 
It can also reduce ICP by CSF drainage and thus improve cerebral perfusion and helps in 
determining prognosis. 
Currently, accurate monitoring requires invasive devices. Parenchymal pressure monitors 
(eg, Camino or Codman) measure ICP via a fiber-optic monitor placed in the subarachnoid 
space. Intraventricular catheters placed via ventriculostomy allow for both measurements of 
ICP and drainage of CSF. This device offers a therapeutic advantage over subarachnoid 
monitors but carries a higher incidence of infection(83,85). 
Maintenance of adequate CPP(84,86, 89,90) is accomplished by reducing the ICP and ensuring 
adequate MAP. Adequate CPP and reducing ICP Interventions are used step by step. 
The first step typically includes the use of analgesia and sedation, elevation of head, airway 
and ventilatory management and preferably with concomitant monitoring of jugular venous 
saturation(86,88-90) Obtunded patients, especially those with a GCS ≤ 8 require intubation for 
airway protection. Mechanical ventilation will also facilitate deep sedation and 
hyperventilation. During mechanical ventilation hypercarbia should be avoided because it 
causes vasodilation and may further increase ICP. Therapeutic hyperventilation decreases 
ICP via vasoconstriction cerebral vessels. Also it must be thought that hyperventilation is 
rapidly effective but may lead to reduce CBF and may not be a reasonable long-term 
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strategy. Therefore, it is recommended that maintaining the PaCO2 at the low end of normal 
level is more definitive strategies for reducing ICP. 
The second step includes using mannitol or hypertonic saline infusions for refractory 
intracranial hypertension. In the third step rescue therapies such as high-dose barbiturate 
infusions and possibly decompressive craniectomy or hypothermia may be needed. Thus, 
interventions are traditionally chosen in the order of an increasing risk of complications. The 
goal for patients presenting with raised ICP is reduce ICP immediately ( Table 8). 
 
1. Assessment and management of ABC’s (airway, breathing, circulation) 
2. Early intubation if; GCS <8, evidence of herniation, apnea, inability to maintain 
airway 
3. Mild head elevation of 15–30° (Ensure that the patient is euvolemic) 
4. Hyperventilation: Target PaCO2:30–35 mm Hg (suited for acute, sharp increases in 
ICP or signs of impending herniation) 
5. Mannitol: Initial bolus: 0.25–1 g/kg, then 0.25–0.5g/kg,q 2–6 has per requirement, up 
to 48 h 
6. Hypertonic Saline: Preferable in presence of hypotension, hypovolemia, serum 
osmolality >320 mOsm/kg, renal failure, dose: 0.1–1 ml/kg/hr infusion, target Na+ 
145–155 meq/L. 
7. Steroids: Intracranial tumors with perilesional edema, neurocysticerocosis with high 
lesion load, pyomeningitis, abscess 
8. Adequate sedation and analgesia 
9. Prevention and treatment of seizures: use lorazepam or midazolam followed by 
phenytoin as initial choice. 
10. Avoid noxious stimuli: use lignocaine prior to ET suctioning [nebulized (4% lidocaine 
mixed in 0.9% saline) or intravenous (1–2 mg/kg as 1% solution) given 90 sec prior to 
suctioning] 
11. Control fever: antipyretics, cooling measures 
12. Maintenance IV Fluids: Only isotonic or hypertonic fluids (Ringer lactate, 0.9% Saline, 
5% D in 0.9% NS), No Hypotonic fluids 
13. Maintain blood sugar: 80–120 mg/dL 
14. Refractory raised ICP: 
 Heavy sedation and paralysis 
 Barbiturate coma 
 Hypothermia 
 Decompressive craniectomy 
 
Table 8. Treatment to reduce intracranial pressure.  
Osmotic Diuresis 
Mannitol 
The optimal dosing of mannitol is not known. Mannitol is used as a rapid and effective 
method for reducing ICP. It is given as a 0.5- to 1g/kg bolus and repeat every 6-8 hours to 
maintain serum osmolarity ebow the value of 310 mOsm/L. Mannitol results osmotic 
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diuresis. The altered osmolar gradient facilitates fluid shifts and reduces cerebral edema. 
Similarly, furosamide increases intravascular oncotic pressure via hypoosmolar diuresis, 
which reduces cerebral edema and CSF production and is synergistic with mannitol. These 
agents should be used with caution because hypovolemia and hypotension may result, 
further impairing CPP(84,91,92). Urine output should be matched with crystalloid replacement 
to maintain intravascular volume. 
Attention has to be paid to the fluid balance so as to avoid hypovolemia and shock. There is 
also a concern of possible leakage of mannitol into the damaged brain tissue potentially 
leading to “rebound” rises in ICP (93). For this reason, when it is time to stop mannitol, it 
should be tapered and its use should be limited to 48 to 72 h. Mannitol can also lead to 
hypokalemia, hemolysis and renal failure. 
Hypertonic Saline 
Hypertonic saline has an obvious advantage over mannitol in children who are 
hypovolemic or hypotensive. These may be preferred are renal failure or serum osmolality 
>320 mosmol/Kg too. It has been found effective in patients with serum osmolality of up to 
360 mosmol/Kg(94). The expected complications with the use of hypertonic saline are 
bleeding, rebound rise in ICP, hyperchloremic acidosis and hypokalemia, central pontine 
myelinolysis, acute volume overload, renal failure, cardiac failure or pulmonary edema (95-
97). In different studies the concentration of hypertonic saline used has varied from 1.7% to 
30% (98). There are also a variety of application method and evidence-based 
recommendations are difficult. It would be reasonable to administer hypertonic saline as a 
continuous infusion at 0.1 to 1.0 mL/kg/hr, to target a serum sodium level of 145–155 
meq/L (99,100) Serum sodium level and neurological status should be closely monitored 
during treatment. While finishing hypertonic saline treatment, serum sodium should be 
slowly returned to normal values (hourly decline in serum sodium of not more than 0.5 
meq/L) to avoid complications related to fluid shifts(101). Monitoring of serum sodium and 
serum osmolality should be done every 2–4h till target level is reached and then followed up 
with 12 hourly estimations. Under careful monitoring, hypertonic saline has been used for 
up to 7 days (102). 
Sedatives, analgesics, and neuromuscular blocking agents 
Agitation and the painful stimuli may significantly increase ICP in traumatic brain injury 
patients, and therefore, the use of sedative agents is important in ICP management. A 
variety of pharmacological agents have been suggested to treat agitation. But no optimal 
sedative regimen has been exactly identified. 
Sedatives, analgesics, and neuromuscular blocking agents are commonly used in the 
management of traumativ brain injury. This agents are used for two purposes, emergency 
intubation and management including control of ICP in the intensive care unit (ICU). 
Pain and agitation produce sympathetic hyperactivity, resulting in an increase in heart rate, 
stroke volume, myocardial oxygen consumption and ICP and should be avoided. Analgesia 
and sedation reduce the neuro-endocrine response to stress by resulting an increase in 
adrenocorticotrophic hormone (ACTH), cortisol, antidiuretic hormone (ADH), growth 
hormone (GH) and glucagon. The stress response reduces insulin uptake, causing 
hyperglycaemia, relative glucose intolerance and insulin resistance, and promotes 
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catabolism of proteins and lipids and a decrease in gastrointestinal motility and urine 
output. 
Benzodiazepines 
The benzodiazepines are the favoured group of drugs for sedation and are divided into 
short-acting, intermediate-acting and long-acting drugs. Among them midazolam, 
lorazepam and diazepam are mostly used.  
Midazolam (Dormicum) is short-acting benzodiazepine and 2-3 times more potent than 
diazepam, and is available in three strengths. Midazolam is well known for its idiosyncratic 
effects. It has active metabolites, and can accumulate. Its duration of action is approximately 
45 minutes. The adult loading dose is 2 mg intravenously over 30 seconds. The maximum 
effect is in 3 minutes. After 3 minutes, increments of 1 mg can be given every 3 minutes until 
the desired effect is achieved. Midazolam may cause respiratory depression. Elderly patients 
should be given half of the above recommended dosage. Midazolam can be used orally, 
rectally, intranasally, or intravenously in children. The recommended paediatric doses are as 
follows: intranasal 0.4 mg/kg, oral/rectal 0.5 mg/kg, intravenous 0.1 mg/kg. 
Lorazepam (Ativan) is an intermediate-acting benzodiazepine which has no metabolites. It 
is useful in acute anxiety, acute phsychosis and status epilepticus. The maximum safe adult 
dosage is 4 mg and the minimum effective dose should be titrated to the individual patient’s 
needs. The intravenous dose for children is 0.1 mg/kg. 
Diazepam (Valium) is a long-acting benzodiazepine which is less potent than the previous 
two. It has active metabolites, and a sclerosing effect on veins. The intravenous dosage of 0.1 
mg/kg applies to both adults and children, and the rectal dosage is 0.5 mg/kg. 
α-2 receptors agonists 
Sedative and hypnotic effects of these drugs are due to the action on ǂ2-receptors in the 
locus ceruleus. Analgesic effect is maintened by an action on ǂ2-receptors within the locus 
ceruleus and the spinal cord. These are dextmedetomidine and clonidine. 
Dexmedetomidine (Precedex) is a new selective ǂ-2 adrenoreceptor agonist drug. It has both 
anxiolytic and analgesic properties. It does not cause respiratory depression, and patients 
maintain cognitive function and are easily rousable. The bradycardia and hypotension may 
be seen as side effects. There is no effect on ICP, but CPP may decrease by virtue of 
decreasing MAP. 
Anaesthetics 
Propofol and thiopentone are used for sedation and lowering ICP in traumatic brain injuried 
patients. 
Propofol 
- Mechanisms of actions: 
- Acts on GABAǂ receptors in the hippocampus. 
- Inhibition of NMDA receptors. 
- Ņ IOP, ICP & CMRO2 
Propofol is widely used in the ICU to sedate intubated neurolojic patients with increased 
ICP(94). Propofol has been shown to maintain or reduce ICP while maintaining an adequate 
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CPP(95). Propofol has also neurovascular, neuroprotective, and electroencephalographical 
effects that are salutory in the patient in neurocritical care. The short half-life of propofol 
facilitates serial neurologic exams and is the prefered agent. However, excessive sedation 
and analgesia may mask examination findings and prolong the course of mechanical 
ventilation(82,88,104). 
Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up 
to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 48 h or until 
removal of the ICP or when mechanical ventilation is discontinued. 
Propofol is employed as a first-line sedative agent in neurosurgecal patients due to its 
favorable pharmacokinetic profile (105) . However, some patients require prolonged infusions 
and high rates of propofol. This has been shown increase their risk for development of a 
severe propofol-related infusion syndrome, which can be fatal. Propofol infusion syndrome 
is expected in ebow 5 mg/kg/hr infusion more than 48 hours. Its clinical features consist of 
cardiomyopathy with acute cardiac failure, myopathy, metabolic acidosis, hiperkalemia and 
hepatomegaly. Mechanism of this syndrome is by though inhibition of free faty acids entry 
into mitochondria and failure of its metabolism. Both barbiturates and propofol have 
favorable effects on cerebral oxygen balance, but propofol is more potent in this regard. 
Benzodiazepines and propofol have the added benefit of increasing the seizure threshold. 
Barbiturates act on the GABA receptors and its mechenism of action in zero order kinetics. It 
provides a cerebral protection effect and uses in neurointensive care units in patients with 
high ICP and status epilepticus. 
Barbiturates are less effective than mannitol for lowering ICP. Thiopentone can be used for 
this purpose and the dosing of the drug is adjusted to a target ICP as monitored on an ICP 
monitor. The drug is titrated to a 90% burst suppression (2–6 bursts per minute) using an 
EEG monitor. Monitoring in barbiturate coma should include EEG, ICP monitoring, 
invasive hemodynamic monitoring (arterial blood pressure, central venous pressure, SjvO2) 
and frequent assessment of oxygenation status. The complication rate of barbiturate therapy 
is high and includes hypotension, hypokalemia, respiratory complications, infections, 
hepatic dysfunction and renal dysfunction (106). 
Opiods: 
Morphine, fentanyl and remifentanil can be used not only pain management but also 
sedation effect. Morphine and fentanyl are the two most commonly used opioids for the 
analgesia of critically ill patients(107,108). They are routinely used in patients with severe head 
injury as part of the management of increased intracranial pressure (ICP). However, the 
cerebrovascular effects of such drugs remain controversial. Studies in laboratory animals 
and humans have shown increases, decreases or no change in ICP after opioid 
administration(109-120). Most of these studies find a concomitant decrease in systemic arterial 
pressure and, recently, it has been suggested that reduced MAP could in fact be responsible 
for the increases in ICP observed after the administration of potent opioids such as 
sufentanil(107). In patients with low intracranial compliance and intact autoregulation, 
reduced MAP would be expected to result in vasodilation, increased blood volume, and 
thus increased ICP. 
Remifentanil is a selective mu-opioid agonist with a context-sensitive half-time of 3 to 5 
minutes, independent of dose or administration duration of. Its metabolism by nonspecific 
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esterases results in rapid and uniform clearance leading to highly predictable onset and 
offset of action. Other desirable effects include decreased cerebral metabolism and decrease 
intracranial pressure (ICP) with minimal cerebral perfusion pressure changes . 
Neuromuscular blockade 
Neuromuscular blocking agents can facilitate mechanical ventilation and management of 
raised ICP, but their use should be reserved for specific indications. The depth and duration 
of neuromuscular blockade should be monitored and optimized, respectively. Although 
therapeutic paralysis may in a fall in ICP and prevents shivering if induced hypothermia is 
attempted. However, it may mask seizure activity, negates the physical exam potentially 
delaying early signs for deterioration, prolongs ventilation, and increases the risk for 
pressure ulcers and venothromboemboli (121). Deep sedation may be safer while providing 
similar benefits(122). 
Hypothermia 
Hyperthermia increases ICP and should be prevented. Moderate hypothermia can help to 
control critically elevated ICP values in severe space-occupying edema. 
The basic mechanisms through which hypothermia protects the brain are clearly 
multifactorial and include at least the following: reduction in brain metabolic rate, effects on 
cerebral blood flow, reduction of the critical threshold for oxygen delivery, blockade of 
excitotoxic mechanisms, calcium antagonism, preservation of protein synthesis, reduction of 
brain thermopooling, a decrease in edema formation, modulation of the inflammatory 
response, neuroprotection of the white matter and modulation of apoptotic cell death (123). 
Hypotermia have some risks include coagulopathy and electrolyte abnormalities. Shivering 
may occur, which will increase ICP(88,124). 
Glycemic control; Hyperglycemia has an adverse effect on outcomes in neurointensive 
patients and should be aggressively treated(125). 
CSF drainage: The role of CSF drainage is to reduce intracranial fluid volume and thereby 
lower ICP. Removal of CSF through an intraventricular catheter reduces ICP. Drainage 
should be continued to maintained the ICP between 5 mm Hg and 15 mm Hg(126,127). 
Craniectomy: Although drastic, bone and potentially brain removal are extremely effective 
in reducing ICP. Craniectomy greatly facilitates ICP management and may improve 
outcomes and is recommended if other therapies are not effective (128). 
Intensive Care Unit Complications 
Intensive care unit complications are very various because the illnesses affecting the various 
organ systems and the interventions put in the practise on the patients as a means of getting 
health. The patients being in neurointensive care unit would be expected more diferent 
diversty complications. 
Pulmonary Complications 
Pulmonary complications like nasocomial pneumonia, ARDS progressed in mechanicaly 
ventilated patients, neurogenic pulmonary oedema, pulmonary embolism are discussed 
below. 
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Nosocomial pneumonia 
According to American Thoracic Society (ATS) guidelines, nosocomial pneumonia (also 
known as hospital-acquired pneumonia or health care–associated pneumonia) is defined as 
pneumonia that occurs more than 48 hours after hospital admission but that was not 
incubating at the time of admission. 
Ventilator-associated pneumonia 
Ventilator-associated pneumonia (VAP) is becoming common nosocomial infection in 
hospitals with devolopment of intensive care units(129). VAP is defined as pneumonia that 
develops in 48 hours mechanicaly ventilated patients. The mechanism of VAP progresion is 
retrograde colonisation of the oropharynx caused by gastro-oesophageal reflux and possibly 
also cross colonisation from contaminated hospital personnel or equipment. In addition 
many mechanically ventilated patients are immobile and cannot expand the distal airways 
with sighs, deep breaths, and coughs. The main pathogens of VAP are Pseudomonas 
aeruginosa, Enterobacteriaceae, and other Gram-negative bacilli, Streptococcus faecalis, 
Staphylococcus aureus, Candida sp, Aspergillus sp, and episodes of polymicrobial 
pneumonia etc. Mortality rates, morbidity, and costs are all increased in the patient with 
VAP because the treatment of it is difficult and expensive. Early-onset VAP has almost no 
risk for having multidrug-resistant (MDR) pathogens. Currently recommended initial 
empiric antibiotics include ceftriaxone, fluoroquinolones, ampicillin-sulbactam or 
ertapenem. Late-onset VAP has a risk of having MDR pathogens. Their initial 
antibiotherapy may consist antipseudomonal cephalosporins (eg, cefepime, ceftazidime), 
antipseudomonal carbapenems (imipenem or meropenem), beta-lactam/beta-lactamase 
inhibitors (piperacillin-tazobactam) with an antipseudomonal fluoroquinolone 
(ciprofloxacin) or aminoglycoside plus linezolid or vancomycin (if risk factors for 
methicillin-resistant Staphylococcus aureus are present). If infection with Legionella 
pneumophila is suspected, the regimen should include a macrolide or fluoroquinolone 
rather than an aminoglycoside. Early administration of appropriate antibiotic regimens and 
with adequate dosing of antibiotics improve outcomes after VAP. Antibiotics should be 
further adjusted on the basis of culture results. The first antibiotic regimen must be 
optimized, because inappropriate initial therapy is associated with worsened outcomes, 
even if the regimen is subsequently changed on the basis of the microbiologic results. 
Aspiration pneumonia 
Aspiration pneumonia is usually caused by colonisation of aerobic bacteria from gastric and 
oesophageal flora because of repeated small volume aspiration during sleep, especially with 
impaired pharyngeal reflex (130). It usually develops subclinically and fulminant aspiration 
syndrome is rare. There may be no symptoms before the development of transient 
hypoxaemia or infiltrates on x-ray. Increasing pulmonary artery pressure because of 
hypoxaemic vasoconstriction and pulmonary oedema developing secondary to acid induced 
lung damage. Chest X-Ray usually shows right lower lobe infiltration, atelectasis, and 
sometimes shows air bronchogram with bilateral, diffuse infiltrates. Treatment must be 
planed on the base of antibiograme results of tracheal and blood culture. 
Adult respiratory distress syndrome 
ARDS is a severe lung disease caused by a variety of directly and indirectly pertaining the 
lungs. It is characterized by inflammation of the lung paranchyme leading to impaired gas 
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exchange with concomitant systemic release of inflammatory mediators causing 
inflammation, hypoxemia and frequently resulting in multiple organ failure. This condition 
is often fatal, usually requiring mechanical ventilation and admission to an intensive care 
unit. A less severe form of this fulminanat lung disease is called acut lung injury (ALI). 
Before thinking ARDS any cardiogenic cause of pulmonary edema should be excluded(131). 
ARDS is a form of non-cardiogenic pulmonary oedema characterised by reduced respiratory 
compliance and increased work of breathing and V/Qmismatch, leading to an increased 
shunt and hypoxaemia. The definition of ARDS is based on the table below. 
 
 Acute onset 
 Pulmonary artery wedge pressure ≤18 mmHg or absence of clinical evidence of left 
atrial hypertension 
 Bilateral infiltrates on chest radiography 
 Acute lung injury (ALI) is present if Pao2/Fio2 ratio is≤ 300 
 Acute respiratory distress syndrome is present if Pao2/Fio2 ratio ≤ 200 
Table 9. ARDS criteria. 
ARDS may follow any major illness, sepsis or surgery but is common following aspiration 
or septicaemia. Multiorgan failure may occur and is a common cause of death. The 
treatment of ARDS consist of apropirate managment of ventilatory support. Ventilatory 
support is arraenged for adequate oxygenation with different strategies. As saying baby 
lung ventilation with low tidal volumes between 5 and 6 mL/kg or predicted body weight 
are used. The aim this is to save the healty lung reagions from excessively high inflation 
pressures. The management depends on the recruitment of collapsed alveoli with PEEP to 
correct the pronounced ventilation–perfusion mismatch and to prevent compression 
atalectasis. The peak inspiratory (plateau) pressure should be kept below 30-35 cm water, 
and as possible as eucapnia should be maintained to avoid further increases in intracranial 
pressure. High levels of PEEP may be required to treat severe hypoxemia. Caution is 
advised, however, because PEEP can inhibit cerebral venous return and increase intracranial 
hypertension. 
Neurogenic pulmonary oedema 
Neurogenic pulmonary edema (NPE) is defined as an increase in pulmonary interstitial and 
alveolar fluid (132-135)developing after an acute injury to the brain or brainstem in patients 
with intracranial pathology, including subarachnoid haemorrhage, cerebral emboli, cerebral 
tumours, status epilepticus, and raised intracranial pressure (ICP). The increased 
intracranial pressure is thought to precipitate an increased central sympathetic nerve 
activity transmitted via peripheral alpha and beta-adrenergic receptors. Neurogenic 
pulmonary edema results from a predominant alpha-receptor stimulation with a significant 
increase in the preload and afterload. The patient may present with excessive sweating, 
hypertension, tachypnoea, and frothy sputum. Chest X-Ray shows diffuse pulmonary 
infiltrates, but the diagnosis depends on showing hypoxaemic respiratory failure with a 
normal pulmonary artery wedge pressure in the absence of a cardiac cause. Supplemental 
oxygen is required in most patients to correct hypoxemia. Mechanical Ventilation may be 
necessary, either noninvasive with a face mask or via an endotracheal tube. Neurogenic 
pulmonary oedema should be distinguished from aspiration pnomonia, ARDS, and other 
www.intechopen.com
 
Intensive Care Management of the Traumatic Brain Injury 
 
29 
pulmonary diseases. Because treatment of NPE is different. Pharmacological agents are not 
used routinely in the treatment of neurogenic pulmonary edema. Several agents, such as 
alpha-adrenergic antagonists, beta-adrenergic blockers, dobutamine, and chlorpromazine, 
are advocated by some authors, but assessment of their effectiveness is difficult because 
neurogenic pulmonary edema is usually a self-limited condition that resolves 
spontaneously. 
Pulmonary embolism 
Patients with neurological disease are susceptible to deep vein thrombosis (DVT) and 
pulmonary embolism (PE) particularly if they are immobilised or paralysied. PE and DVT 
are two clinical presentations of venous thromboembolism (VTE) and share the same 
predisposing factors. In most cases PE is a consequence of DVT. PE is a relatively common 
cardiovascular emergency and a difficult diagnosis that may be missed because of non-
specific clinical presentation(136). Smaller emboli may cause few haemodynamic effects or 
may result in infarction of a section of lung tissue if collateral blood flow is inadequate. 
Large and/or multiple emboli might abruptly increase pulmonary vascular resistance to a 
level of afterload which cannot be matched by the right ventricle (RV) and right heart failure 
identified acute cor pulmonale may develope. Sudden death may occur, usually in the form 
of electromechanical dissociation(137). 
The treatment of pulmonary embolism depends upon its size. Cardiopulmonary 
resuscitation may be necessary following a massive embolus with the patient in shock 
from acute cor pulmonale, justifying aggressive treatment with thrombolysis. Supportive 
treatment includes correcting hypoxaemia, intravenous fluid replacement, inotropic 
drugs, and analgesia. Mechanical ventilation may be necessary if the patient cannot 
maintain adequate oxygenation. Anticoagulation is usually begun with unfractionated 
heparin, the dose being titrated against the activated partial thromboplastin time. In 
ischaemic stroke, dosage should not be adjusted to lower levels for fear of haemorrhagic 
conversion as an inadequate dose increases mortality from pulmonary emboli. Warfarin 
administration should begin 48 hours after the start of heparin and continue for six 
months thereafter. 
Hypovolaemia 
Hypovolaemia often accompanies traumatic brain injury due to decreased intake and 
increased loss (vomiting, sweating). Fluid should be restricted to those who are in various 
grade of coma and central venous pressure can be measured to guide fluid therapy. Full 
maintenance of sodium should be given as hyponatraemia impairs cerebrovascular 
reactivity and serum sodium level should be maintained above 140mmol/l. 
The choice of fluid replacement depends on a number of factors. If the patient is anaemic 
(haemoglobin < 8 g/dl), transfusion of red cells should be considered, especially if the 
patient has a history of ischaemic heart disease. If the patient’s haemoglobin is above this 
value, blood volume may be increased by the use of colloids or crystalloid solutions. 
Colloids are expensive, carry the risk of anaphylaxis, and the absence of clotting factors may 
precipitate a coagulopathy. Generally, in neurointensive care practice, 0.9% sodium chloride 
solution is favoured over glucose or lactate containing solutions which have the potential to 
increase intracellular glucose concentrations and thus increase the risk of ischaemic damage. 
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Hypo/Hypertension(138-149) 
For ensuring adequate organ perfusion, monitoring and maintenance of arterial blood 
pressure and blood volume in normal limits are essential. Arterial catheterization is 
indicated in ICU setting when abnormal blood pressure threatens to compromise blood flow 
to the brain, exacerbate high intracranial pressure. During hypotension, arterial and jugular 
venous oxygen contents significant decrease. Also hypotension causes inadequate blood 
flow to the brain, especially if intracranial pressure is already elevated. CVP monitoring, 
pulmonary pulmonary artery catheterisation and devices using Doppler principles are used 
to help untangle the explanation of hypotension and allow appropriate treatment. 
Hypertension cause elevation of intracranial pressure and/or increase bleeding into the 
brain and surrounding compartments. Hypertension is a common sequelae of acute 
neurological events. When cerebral autoregulation is disturbed or its limits are exceeded, 
blood flow passively increases with increasing blood pressure. This in turn can increase 
intracranial pressure or cause breakdown of the blood–brain barrier with resultant 
transudation of intravascular fluid. Acute hypertension may also increase morbidity and 
mortality by exacerbating cerebral edema, raising intracranial pressure and bleeding. 
Treatment of hypertension requires carefull consideration. Causes of hypertension 
pertaning with acute neurological events are summerised at the below. 
Causes of hypertension 
Neurological disorders 
 Increased intracranial pressure 
  Brain tumours 
  Encephalitis/encephalomyelitis 
  Respiratory acidosis 
 Acute stress, 
  Psychogenic hyperventilation 
  After resuscitation 
  Hypoglycaemia 
  Hypoksemia 
 Vasoconstrictors/Medications 
  Ephedrine 
  Phenylephrine 
  Pseudoephedrine 
  ǃ-agonist bronchodilators 
  Glucocorticoids 
On the other hand patients with raised ICP require an elevated MAP to maintain an 
adequate cerebral perfusion pressure, and any fall in cerebral blood flow may lead to global 
ischaemia. So treatment of hypertension must be planed according the situation of brain. 
Pharmacotherapy used to treat acute situation may have undesirable effects on cerebral 
perfusion pressure (CPP). Intravenous labetalol, hydralazine, and sodium nitroprusside are 
commonly used drugs. Longer term treatment includes oral ǃ adrenergic receptor 
antagonists, angiotensin converting enzyme inhibitors, and calcium channel antagonists. 
Treatments are indicated if the mean arterial blood pressure is higher than 130 mm Hg or 
cerebral perfusion pressure is higher than 85 mm Hg. 
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Seizures 
Seizures are a common complication of traumatic brain injury, and can occur immediately 
following the injury, or may develop later.The risk of post-traumatic seizure is generally 
related to the severity of the injury. 
Hypo/hypernatremia, hypo/hyperglycemia, hypocalcemia, hypomagnesemia, 
hyperosmolarity, hypoxia and uremia can also lead to seizures. Many antibiotics often used 
in co-existant infections such as quinolones, third or fourth generation cephalosporins and 
meropenem may presipitate or aggrevate seizures. 
Subclinical seizures or status epilepticus were associated with episodic clinically relevant 
increases in ICP. Often, subclinical status epilepticus is neither diagnosed nor treated in the 
ICU, and may be a target in neurointensive care for improving patient outcomes. Use of 
continuous EEG monitoring represents an important research priority. 
As a complication of infection(150-154)seizure may seen only one single attact or may become a 
chronic epilepsy. Seizures may arise as an acute, subacute, or long- term consequence of an 
infectious state. 
The patients with fever and having alteration in sensory status may be associated with focal 
neurological signs and seizures. Febrile seizures occur with a prodromal fever. A simple 
febrile seizure occurs as a brief generalized tonic clonic seizure occurring after the onset of 
fever. A complicated febrile seizure is occure with prolonged seizure activity or focal seizure 
activity. 
The use of antiepileptic drugs to arrest the seizures and other general measures including 
the use of antibiotic and antiviral drugs, electrolyte and fluid management, blood pressure 
monitoring, respiratory monitoring and other aspects of intensive care are equally 
important. . 
Management and goals of seizures 
Treatment of a patients with seizures requires: 
- Maintenance of vital functions 
- Abolition of seizures 
- Elimination of any precipitating factors 
- Reversing correctable causes 
Following protocols for management is vital. 
The initial treatment is directed towards: 
- Maintaining an airway. 
- Supporting breathing and administration of oxygen. 
- Support and maintenance of vital functions 
The clinician should first search for underlying etiologies producing the seizures and treat it 
(hypoglycemia, hypocalcemia, sepsis). There are many different types of seizure medication 
used to treat many different types of seizures(155). Examples of first -line medications are 
carbamazepine (Tegregol, Carbatrol), valproate (Depakote), phenytoin (Dilantin) and 
ethosuximide (Zarontin). Additional medications known as add-on medications or second-
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line therapy may be required in addition to first -line medications. Examples of second-line 
seizure drugs include gababentin (Neurontin), lamotrigine (Lamictal) and topiramate 
(Topamax). Loss of cerebral autoregulation and neuronal damage begin after 30 minutes of 
continuous seizure activity. Lorazepam is better than diazepam or phenytoin alone for 
cessation of seizures and carries a lower risk of continuation of status epilepticus requiring a 
different drug or general anaesthesia. 
Fever (156-162) 
Fever is among the most frequently detected abnormal physical signs in critically ill patients 
and may arise due to infectious or noninfectious etiologies. Fever is a complex adaptive 
response involving elaborate interactions between the immune and nervous systems. High 
temperatures inhibit growth of microorganisms, may reduce the expression of virulence 
factors, increase susceptibility to anti-microbials and enhance host immune responses. At 
the same time fever can worsen primary brain damage. Because increase in cerebral oxygen 
consumption may leads to increase in blood flow and accordingly in blood volume. This 
increase potentiates neurologic injury and causes brain edema. Fever is deleterious in 
patient with low cerebral compliance and generate dangerous intracranial pressure rises 
accelerating the terminal stages of fulminant infections (through cytokine-induced tissue 
injury). 
Non-infectious causes of fever are common in the ICU. Transfusion reactions and drug 
hypersensitivity, in particular to anti-microbial agents, are frequent causes. Deep vein 
thrombosis, pulmonary embolus/infarct, myocardial infarction and acute haemorrhage may 
also cause fever. Neurogenic fever usually is caused by damage to the hypothalamus from 
CNS trauma, intracerebral bleeding, or an increase in intracranial pressure. Neurogenic 
fevers are characterized by a high temperature that’s resistant to antipyretic therapy and 
isn’t associated with sweating. 
Fever treatment methods may include direct cooling and anti-pyretic medications such as 
acetylsalicylic acid, non-steroidal anti-inflammatory agents and acetaminophen. An 
alternative method for temperature management may be an intravascular approach. 
Direct cooling is done by many methods for example reducing the ambient room 
temperature, application of cool external substances such as mist, ice packs, wet sponges 
and cooling blankets, and administration of cooled intravenous fluids(161,162). A number of 
newer techniques have evolved including cooling jackets and intravascular catheter-based 
heat exchange systems. Convective cooling (ie, blowing cold air) is thought to be more 
effective than cooling blanket for decreasing body temperature and is also thought to be 
more comfortable for patients. Administration of ice cold intravenous fluid also directly 
cools core tissues and has been used for his purpose in physiologic studies. The method is 
obviously restricted by the volume that can be administered without overloaing the 
cardiovascular system. 
Aggressive fever treatment strategy ; Acetaminophen ( Adults 0.5-1 gm, every 4-6 hours 
upto a maximum of 4 gms. Children 10 mg/kg, every 4-6 hours) for fever >38.5°C and a 
cooling blanket added if >39.5°C) .Routes of Administration Oral, Parenteral (I.M.). Never 
IV use with great caution in patients with hepatic dysfunction and in alcoholics. 
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Intensive Care Nursing 
Traumatic Brain İnjury can be fatal if it is not diagnosed and treated promptly; even with 
treatment, some patients have CNS damage and serious permanent neurologic problems at 
the end of disease. 
The critical-care nurse must be alert with the potential problems encountering the brain-
injured patient, who has the risk of sudden deterioration at any time. 
Managing a patient with TBI requires a well-defined plan, plenty of resources, and an 
organized team to prevent secondary injuries. Nursing interventions for TBI are performing 
frequent vital signs and neurologic assessments for signs of disease progression, such as 
decreased level of consciousness and assessing mental status, muscle strength, headache 
severity, and pupillary reactions. An important nursing care for TBI is raising the head of 
the bed 30 degrees, these intervention promote cerebral venous drainage and to prevent 
increased ICP. Routine caring like maintaining a patent airway, suctioning the patient as 
needed and positioning him to encourage drainage of oral and nasal secretions is also 
essential. Monitorizing oxygenation, administering supplemental oxygen if indicated and 
monitorizing arterial blood gas analysis results is needed for planing of treatment. Reducing 
stimuli around the patient, and avoiding Valsalva maneuver, i.e., coughing, sneezing and 
straining during bowel movements are important intervention in progression of TBI . 
Keeping the patient's room quiet and darkened can make more comfortable and reduce 
agitation. An indwelling urinary catheter for accurate intake and output monitoring should 
be performed. 
Patients with TBI frequently have hyperthermia, or fever. Nursing interventions includes 
reducing fever, not only for a patient's discomfort, but because fever causes increase in 
intracranial pressure. Nursing care plans that for reducing hyperthermia in TBI patients 
should include monitoring body temperature every four hours, administering antipyretics 
and cooling baths as ordered by the physician, and monitoring the patient for signs of 
dehydration. TBI can cause severe headaches and nursing interventions must be planed as 
completly pain-free. Positioning (if it is not contraindicated by ICP) and administering mild 
analgesics to combat discomfort are that can be doing for pain management. It may be 
helpful to cover the patient's eyes with a cool cloth because this will reduce unnecessary 
stimuli and photophobia. 
 Many patients may need mechanical ventilation and endotracheal tube/suctioning can 
increase ICP so that the use of lidocaine IV %2 1.5 – 2 mg/kg iv prior to endotracheal 
suctioning to attenuate the ICP response. 
3. Conclusions 
Traumatic brain injury is a serious public health problem all over the world. Each year, 
traumatic brain injuries contribute to a substantial number of deaths and cases of permanent 
disability. Management of TBI in intensive care is very difficult. Management is becoming 
more difficult when the pulmonary complications and organ dysfunctions added. Disease 
spesific applications are needed in treatment of mechanical ventilation. The aim of mechanic 
ventilation is to maintain adaquate oxgenation and ventilation without increasing ICP. 
Nurition strategy in these patients must be planned to support immune system without 
loading CO2. 
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In conclusion, with the proper support therapy and close management, the mortality and 
morbidity of TBI patients can be decreased. 
4. Abbreviations 
TBI: traumatic brain injury; PaO2: arterial partial pressure of oxygen; PEEP: positive end-
expiratory pressure; PbtO2; brain tissue oxygenation, VILI: ventilator-induced lung injury; 
ICP:intracranial pressure; CBP:cerebral blood flow; CPP: cerebral perfusion pressure; MAP: 
mean arterial pressure; GCS; Glascow coma scale; PECLA:Pumpless extracorporeal lung 
asist; VAP:Ventilatory Associated Pneumonia; ITP: intrathoracic pressure; IV:intravenous; 
ALI:Acute lung injury; ARDS: Acute respiratory distress syndrome; PaO2 : partial pressure 
of arterial oxygen; FiO2:percentage of inspired oxygen; SBI: secondary brain injury; CMRO2: 
cerebral metabolic rate of oxygen consumption; PbtO2:brain tissue oxygenation; TPN: Total 
parenteral nutrition; EN:Enteral nutrition, PN: Parenteral nutrition , MDR:multidrug-
resistant , DVT: Deep vein thrombosis, PE: Pulmonary embolism 
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